ABPI

Three Questions: Norman Goldfarb, MAGI

Monday, May 15, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Suz Redfearn spoke with Norman Goldfarb, chairman of Model Agreements & Guidelines International (MAGI), an organization that has spent a decade promoting the standardization of clinical trial agreements (CTAs) and contract templates that both sites and CROs or sponsors can use to speed study startup. Goldfarb is also editor of The Journal of Clinical Research Best Practices, and managing director of First Clinical Research. In April, the Association of Clinical Research Professionals gave Goldfarb their award for innovation for the MAGI CTA initiative.

[Read More]

Upcoming EU referendum delays UK pharma market changes

Monday, April 18, 2016

Civil servants must observe a period of “purdah” in the weeks before a general election or referendum, which restricts government activity to avoid unfairly influencing public opinion. This has hit two major consultations for the pharma industry—the Accelerated Access Review (AAR) and proposed changes to the medicines pricing system known as the Statutory Scheme. The AAR is the brainchild of life sciences minister George Freeman, who wants it to re-shape the U.K. market and the National Health Service (NHS) around encouraging medical innovation, and remove some of the blocks and bottlenecks which plague the current system.

[Read More]

Study: Clinical trial transparency improving

Thursday, May 7, 2015

Transparency amongst industry-sponsored clinical trials continues to improve with results of 90% of trials on all new medicines approved by the EMA in 2012 disclosed within a 12-month timeframe, according to an Association of the British Pharmaceutical Industry (ABPI) study.

[Read More]